ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

REPL vs IMCR // EV/EBITDA & P/E VALUATION

Replimune Group Inc. (NASDAQ) VS. Immunocore Holdings plc (NASDAQ) • 15-METRIC TALLY: REPL 2 — IMCR 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (REPL VS. IMCR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC REPL IMCR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 96.00% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -17.01% -0.93% -16.08 IMCR /fcf-yield <GO>
Operating Margin — -11.30% — TIE /operating-margins <GO>
Net Profit Margin — -8.90% — TIE /net-margins <GO>
Revenue Growth (YoY) — 29.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 1.40 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 5/9 -2.00 IMCR /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 75.1 46.4 +28.73 REPL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.65B $1.61B $38.2M REPL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR REPL REV IMCR REV REPL GROSS % IMCR GROSS % REPL FCF IMCR FCF
FY 2025 $0 $400.0M — 98.0% -$280.3M -$15.1M
FY 2024 $0 $310.2M — 98.0% -$192.3M $20.9M
FY 2023 $0 $249.4M — — -$185.5M $2.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
REPL // BETA —
IMCR // BETA —